non-enantiomer analysis
非对映异构体分析
identifying non-enantiomers
识别非对映异构体
non-enantiomer content
非对映异构体含量
presence of non-enantiomers
非对映异构体的存在
non-enantiomer separation
非对映异构体分离
detecting non-enantiomers
检测非对映异构体
non-enantiomer impurity
非对映异构体杂质
non-enantiomer ratio
非对映异构体比例
assessing non-enantiomers
评估非对映异构体
non-enantiomer standard
非对映异构体标准
the drug candidate was identified as a non-enantiomer, complicating the synthesis process.
该药物候选物被确定为非对映异构体，这使得合成过程复杂。
our research focused on the separation of a non-enantiomer mixture using chiral chromatography.
我们的研究重点是使用手性色谱法分离非对映异构体混合物。
the non-enantiomer exhibited significantly lower biological activity compared to the desired enantiomer.
该非对映异构体表现出比所需对映异构体明显较低的生物活性。
we analyzed the product to confirm the absence of a non-enantiomer impurity.
我们分析了产品以确认非对映异构体杂质的存在与否。
the non-enantiomer's properties were thoroughly investigated for potential applications.
对该非对映异构体的特性进行了全面调查，以寻找潜在的应用。
the synthesis yielded a racemic mixture containing a non-enantiomer component.
合成产物得到的是一种外消旋混合物，含有非对映异构体成分。
regulatory guidelines require strict control of non-enantiomer levels in pharmaceutical products.
法规要求严格控制药物产品中非对映异构体的含量。
the chiral shift revealed the presence of a non-enantiomer in the sample.
手性位移揭示了样品中存在非对映异构体。
we developed a new method for selectively removing the non-enantiomer from the reaction mixture.
我们开发了一种从反应混合物中选择性地去除非对映异构体的新方法。
the non-enantiomer's impact on the overall reaction kinetics was carefully assessed.
仔细评估了非对映异构体对整体反应动力学的影响。
the presence of a non-enantiomer can affect the drug's efficacy and safety profile.
非对映异构体的存在会影响药物的疗效和安全性特征。
non-enantiomer analysis
非对映异构体分析
identifying non-enantiomers
识别非对映异构体
non-enantiomer content
非对映异构体含量
presence of non-enantiomers
非对映异构体的存在
non-enantiomer separation
非对映异构体分离
detecting non-enantiomers
检测非对映异构体
non-enantiomer impurity
非对映异构体杂质
non-enantiomer ratio
非对映异构体比例
assessing non-enantiomers
评估非对映异构体
non-enantiomer standard
非对映异构体标准
the drug candidate was identified as a non-enantiomer, complicating the synthesis process.
该药物候选物被确定为非对映异构体，这使得合成过程复杂。
our research focused on the separation of a non-enantiomer mixture using chiral chromatography.
我们的研究重点是使用手性色谱法分离非对映异构体混合物。
the non-enantiomer exhibited significantly lower biological activity compared to the desired enantiomer.
该非对映异构体表现出比所需对映异构体明显较低的生物活性。
we analyzed the product to confirm the absence of a non-enantiomer impurity.
我们分析了产品以确认非对映异构体杂质的存在与否。
the non-enantiomer's properties were thoroughly investigated for potential applications.
对该非对映异构体的特性进行了全面调查，以寻找潜在的应用。
the synthesis yielded a racemic mixture containing a non-enantiomer component.
合成产物得到的是一种外消旋混合物，含有非对映异构体成分。
regulatory guidelines require strict control of non-enantiomer levels in pharmaceutical products.
法规要求严格控制药物产品中非对映异构体的含量。
the chiral shift revealed the presence of a non-enantiomer in the sample.
手性位移揭示了样品中存在非对映异构体。
we developed a new method for selectively removing the non-enantiomer from the reaction mixture.
我们开发了一种从反应混合物中选择性地去除非对映异构体的新方法。
the non-enantiomer's impact on the overall reaction kinetics was carefully assessed.
仔细评估了非对映异构体对整体反应动力学的影响。
the presence of a non-enantiomer can affect the drug's efficacy and safety profile.
非对映异构体的存在会影响药物的疗效和安全性特征。
探索常用高频词汇